Skip Navigation

Wake Forest Alzheimer's Disease Core Center


New Alzheimer's Disease Core Center

Wake Forest School of Medicine has been awarded a NIA-funded P30 Alzheimer’s Disease Core Center (ADCC). There are 30 ADCCs nationally, and only 3 Centers in the 12-state Southeastern region, a region with the highest per capita prevalence of Alzheimer’s disease. The ADCC mission is to promote research and education in Alzheimer’s disease both at Wake Forest and nationally. The Wake ADCC has a special focus on the role played by common vascular and metabolic disorders in promoting Alzheimer’s disease, and in developing innovative strategies for prevention and treatment.  

The ADCC is led by Director Suzanne Craft, Associate Directors Jeff Williamson and Laura Baker; Core Leaders Mark Espeland, Stephen Rapp, Kathleen Hayden, Ryan Mott; University of Washington affiliates Thomas Montine and Dirk Keene; and Service Leaders Timothy Hughes, Thomas Register, and Carol Shively.  

The Center will provide extensive resources to Wake Forest investigators to support the development of research and education in Alzheimer’s disease and related disorders. These resources include:

  • Pilot grant funding
  • Referral of well-characterized participants for research studies
  • Extensive data and biospecimen repositories including imaging, blood, cerebrospinal fluid and cognitive/clinical data from well-characterized participants and from non-human primate models
  • Access to a well-characterized brain bank at the University of Washington
  • Consultation regarding formulation of research protocols, grant applications and publications for both human and basic research
  • Training in interdisciplinary research related to Alzheimer’s disease.  

The ADCC will hold an information session for the general public in Spring 2017.

Research to Make a Difference Now and in the Future

The Alzheimer’s Disease Core Center (ADCC) focuses on translational, interdisciplinary research into the pathophysiology, prevention and treatment of Alzheimer’s disease and related dementia disorders. 

Our innovative research examines the changes that occur in the transition from normal aging to mild cognitive impairment and Alzheimer’s disease, and on the contribution of metabolic and vascular factors at the earliest stages of Alzheimer’s disease pathogenesis.

Beyond finding the root causes of Alzheimer’s disease, our program works with a vast network of partners to prevent the development of cognitive impairment and Alzheimer’s disease through cutting-edge clinical trials.

Alzheimer buttonWe are one of only a handful of Alzheimer’s disease research programs in the Southeast. Our location, in the Piedmont Triad region of North Carolina, is in an area whose population has especially high rates of diabetes, hypertension and metabolic disease.

Being located in the heart of this region provides our researchers with a unique opportunity to study individuals who have been diagnosed with specific conditions that may greatly increase their risk factor(s) for developing Alzheimer’s.

In addition, our program builds on the multidisciplinary scientific community at Wake Forest Baptist Medical Center and the J. Paul Sticht Center on Aging and Rehabilitation, one of the first centers in the world to combine comprehensive medical and psychiatric care, assessment, rehabilitation and research for aging under one roof.

Our approach brings together the latest technologies in neuroscience, neuropsychology, brain imaging and new drugs - all helping find new ways to slow brain aging. Ultimately, researchers in the ADCC hope to delay, prevent and ultimately cure Alzheimer’s disease and other dementia disorders.

Why Participate in a Clinical Trial?

There are many reasons why you may want to participate in an Alzheimer’s clinical trial.

You may want to:

  • Help others, including your own family members, who may be at risk for Alzheimer’s disease
  • Receive a thorough cognitive assessment and follow-up over time
  • Learn more about memory and your health
  • Be among the first to learn about promising interventions for the prevention and treatment of Alzheimer’s.
  • Get information about local support groups and available resources

Clinical trials and observational studies allow research professionals to partner with volunteer participants to work together to discover new and effective strategies to prevent and treat Alzheimer’s.

To accomplish this goal, we need all kinds of volunteers to participate in our research studies. This includes: men and women, people from different ethnic and racial backgrounds, people who have been diagnosed with Alzheimer’s, people who have family members with memory problems, people who have certain medical conditions that may increase their risk of developing memory problems, as well as people who are totally healthy.

An intervention may work differently in one group than another.  Without sufficient representation of a certain group, questions about the success of a treatment for members of that group may remain unanswered. Also, without a sufficient number of participants, a study may be delayed or produce limited or inconclusive result findings.


Featured Studies

Steadfast ›

The purpose of this research study is to determine whether an investigational drug, azeliragon (TTP488) is safe and beneficial in delaying or altering the decline in memory...



This 18-month study investigates whether a type of insulin improves memory when administered as a nasal spray to adults with a mild memory impairment or early Alzheimer’s...


A4 Study ›

This 36-month study will test whether a new drug slows the progression of memory loss associated with brain amyloid built-up, thereby delaying Alzheimer’s-related damage in...



This 24-week study seeks to learn how adults with abnormal insulin sensitivity and those with memory/thinking problems respond to two different diets. 



This study that will evaluate an experimental drug that is being developed for people with Alzheimer’s disease to learn if it is safe and effective in slowing decline in...



This observational study will identify early risk factors that predict memory decline and dementia in adults, with or without early signs of memory impairment.

Wake Forest Baptist Ranked among Nation’s ‘Best Hospitals’  26 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.